Among the most significant discoveries in ccRCC genomics are recurrent mutations in chromatin remodeling genes, particularly PBRM1, BAP1, and SETD2. Emerging evidence suggests that defects in these genes impair DNA damage repair pathways, rendering tumor cells vulnerable to specific therapeutic interventions. Importantly, the genetic landscape of ccRCC also shapes the tumor immune microenvironment. Tumors with different driver mutations exhibit distinct patterns of immune cell infiltration, cytokine expression, and checkpoint molecule presentation. For instance, PBRM1-deficient tumors tend to have enhanced immune cell infiltration and may respond differently to immune checkpoint inhibitors compared to BAP1-mutant tumors.